An example section of the situation report showing red, amber or green (RAG) ratings according to the number of stock days of both individual product lines and the therapeutic group as a whole, currently and for an arbitrary projected surge of 90 patients
| Neuromuscular blocking agents (NMBAs) | ||||||||||
| Moiety | Trust stock (mg) | Wholesaler stock (mg) | Total stock (mg) | Mg per patient per day | Current patient number | Model uptake | Stock days (current patient number) | RAG (current patient number) | Stock Days (surge 90) | RAG (surge 90) |
| Maintenance | ||||||||||
| Atracurium | 800 000 | 500 | 800 500 | 1500 | 70 | 85% | 9.0 | Amber | 7.0 | Amber |
| Cisatracurium | 50 000 | 5000 | 55 000 | 600 | 70 | 85% | 1.5 | Red | 1.2 | Red |
| Rocuronium | 1 000 000 | 1 500 000 | 2 500 000 | 1450 | 70 | 85% | 29.0 | Green | 22.5 | Green |
| NMBAs Maintenance Group RAG: | GREEN | GREEN | ||||||||
The stock data are for illustration purposes only.